Results 171 to 180 of about 113,809 (305)

Palbociclib in the Treatment of HR+/ HER2‐ Advanced or Metastatic Breast Cancer in Australia: A Real‐World Retrospective Analysis

Asia-Pacific Journal of Clinical Oncology, EarlyView.
This study investigated the real‐world use of CDK4/6 inhibitors in Australian patients with HR+/HER2‐ advanced or metastatic breast cancer, providing data on patient demographics, treatment patterns, and outcomes with palbociclib. ABSTRACT Background There is limited real‐world data on the use of CDK4/6 inhibitors in Australian patients with HR+/HER2 ...
Louise Nott, Eugene Moylan, Maree Colosimo, Giles Stratton, Thomas Chiu, Mahsa H. Kouhkamari, Maureen Hitschfeld, Jessica Michie, Richard De Boer   +8 more
wiley   +1 more source

Assessing Practice Patterns of Antidepressant Medication and Tamoxifen Use Among Patients With Hormone Receptor-Positive Breast Cancer. [PDF]

Cancer Rep (Hoboken)
Lopetegui-Lia N, Murray A, Ondeck M, Osantowski B, Takkellapati S, Wei W, Maggiotto A, Moore HCF, Roesch E.   +8 more
europepmc   +1 more source

Systemic Therapy Management Strategies for Early‐Stage Breast Cancer in Australia

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Advances in systemic therapy for early‐stage breast cancer in Australia highlight genomic‐guided decisions, subtype‐specific strategies, and emerging targeted and immunotherapies, shaping personalized and de‐escalated treatment approaches. ABSTRACT Breast cancer is the most common cancer among Australian women, with early‐stage disease (Stages I, II ...
Nicholas Zdenkowski, Rachel Dear, Sanjeev Kumar, Hilary Martin, Dhanusha Sabanathan, Stephen J. Luen, Belinda Yeo   +6 more
wiley   +1 more source

Impact of Tamoxifen Only After Lumpectomy for "Good-Risk" Duct Carcinoma In Situ: Combined Analysis of the NRG Oncology/RTOG 9804 and ECOG-ACRIN E5194 Trials. [PDF]

Int J Radiat Oncol Biol Phys
Wright JL, Moughan J, Woodward WA, Rahbar H, Shah AB, Comstock C, Jarvis LA, Tjoe JA, Germain I, Badve SS, Strom E, Recht A, Ling DC, Vallow LA, Stephenson JJ, Currey A, Walker EM, Reiter H, Steinberg ML, Pierce LJ, Winter K, Sparano J, Davidson NE, Wolff A, Mamounas EP, White JR, McCormick B.   +26 more
europepmc   +1 more source

Can Hormonal Therapy Improve the Outcomes of mTESE in Patients With Non‐Obstructive Azoospermia?

Andrology, EarlyView.
ABSTRACT Background Non‐obstructive azoospermia (NOA) represents the most severe form of male infertility. Hypogonadism is common in NOA patients, and normal testosterone (T) levels are considered essential for spermatogenesis. Fertility‐preserving hormonal therapy (FpHT) has been proposed to optimize hormonal milieu and improve sperm retrieval rates ...
Mattia Anfosso, Maria Schubert, Jann‐Frederik Cremers, Sabine Kliesch, Michael Zitzmann, Simone Bier   +5 more
wiley   +1 more source

[Corrigendum] Rapamycin enhances the sensitivity of ER‑positive breast cancer cells to tamoxifen by upregulating p73 expression. [PDF]

Oncol Rep
Zhu L, Li XX, Shi L, Wu J, Qian JY, Xia TS, Zhou WB, Sun X, Zhou XJ, Wei JF, Ding Q.   +10 more
europepmc   +1 more source

Mechanisms of Resistance to Antiestrogens and Their Implications for Crossresistance

The first triphenylethylenes considered for clinical use were generated in the mid 1950’s. These compounds were initially generated as fertility agents, e.g.,ethamoxytriphetol (MER-25), and clomiphene.
Clarke, Robert, Lippman, Marc E
core   +1 more source

Peripheral targets for neuropathic pain

British Journal of Pharmacology, EarlyView.
Neuropathic pain represents a significant clinical challenge, with still limited pharmacological approaches to symptomatic relief. This review focuses on molecular targets implicated in neuropathic pain, particularly those involved in peripheral mechanisms. Using the IUPHAR/BPS database of biological targets, their occurrence together with ‘neuropathic
Amirhossein Afsharipour, Cosmin I. Ciotu, Felix J. Resch, Michael J. M. Fischer   +3 more
wiley   +1 more source

GPR75 genetic manipulations in mice reveal central mechanism for weight loss independent of developmental effects. [PDF]

Mol Metab
Lin HV, Gaidarov I, Militello G, Hunt KW.   +3 more
europepmc   +1 more source

O‐GlcNAcylation of KAT2A Enhances Bladder Cancer Proliferation by Inhibiting the KAT2A‐TRIM22 Interaction

Cancer Science, EarlyView.
Lysine acetyltransferase 2A (KAT2A) is a transcriptional coactivator and a member of the Histone Acetyltransferase (HAT) family. While altered KAT2A activity has been implicated in various cancers, its role in bladder cancer (BLCA) remains poorly understood.
Wenjie Yang, Zhaoheng Jin, Ziyi Li, Weifeng Xu, Yingjie Li, Yueqiang Peng, Jie Dong, Lin Ma, Zhigang Ji   +8 more
wiley   +1 more source